{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:03:57Z","timestamp":1768032237066,"version":"3.49.0"},"reference-count":27,"publisher":"Ordem dos Medicos","issue":"10","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Med Port"],"abstract":"<jats:p>O v\u00edrus citomeg\u00e1lico (CMV) \u00e9 um tipo de v\u00edrus de \u00e1cido desoxirribonucleico de dupla cadeia que pertence \u00e0 fam\u00edlia herpesviridae. Ap\u00f3s uma infe\u00e7\u00e3o prim\u00e1ria, o v\u00edrus torna-se latente em v\u00e1rios tipos de gl\u00f3bulos brancos. A infe\u00e7\u00e3o por CMV pode permanecer latente ou tornar-se ativa, especialmente em indiv\u00edduos imunodeprimidos, como aqueles submetidos a transplantes de c\u00e9lulas progenitoras hematopoi\u00e9ticas (TPH), onde a reativa\u00e7\u00e3o do CMV pode ocorrer. Neste contexto, a infe\u00e7\u00e3o por CMV \u00e9 comum e associada a elevadas taxas de morbilidade e mortalidade. A pneumonite \u00e9 uma das complica\u00e7\u00f5es mais graves, com taxas de mortalidade superiores a 50%. Al\u00e9m disso, mesmo na aus\u00eancia de doen\u00e7a espec\u00edfica do \u00f3rg\u00e3o, a infe\u00e7\u00e3o por CMV est\u00e1 relacionada com um aumento da mortalidade n\u00e3o relacionada com a recidiva da neoplasia hematol\u00f3gica. Dada a frequ\u00eancia e gravidade desta infe\u00e7\u00e3o em doentes submetidos a TPH, \u00e9 crucial implementar estrat\u00e9gias eficazes de monitoriza\u00e7\u00e3o, preven\u00e7\u00e3o e tratamento. Este protocolo foi desenvolvido para identificar os grupos de doentes que se beneficiam de uma abordagem sistematizada para a infe\u00e7\u00e3o por CMV e definir a estrat\u00e9gia mais adequada para cada grupo. A monitoriza\u00e7\u00e3o da carga viral de CMV no sangue perif\u00e9rico \u00e9 fundamental, especialmente em doentes com risco moderado a elevado de infe\u00e7\u00e3o ativa. A profilaxia prim\u00e1ria com letermovir (f\u00e1rmaco antiviral) \u00e9 recomendada para reduzir a incid\u00eancia de infe\u00e7\u00e3o ativa, especialmente em doentes com alto risco. A profilaxia secund\u00e1ria com valganciclovir (f\u00e1rmaco antiviral) \u00e9 recomendada ap\u00f3s um epis\u00f3dio de infe\u00e7\u00e3o ativa, enquanto o tratamento de antecipa\u00e7\u00e3o e de doen\u00e7a \u00e9 baseado na monitoriza\u00e7\u00e3o da carga viral e na resposta cl\u00ednica. Este protocolo visa melhorar a abordagem da infe\u00e7\u00e3o por CMV em doentes submetidos a TPH, garantindo uma abordagem preventiva e terap\u00eautica eficaz e segura.<\/jats:p>","DOI":"10.20344\/amp.21441","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T18:27:23Z","timestamp":1721068043000},"page":"733-740","source":"Crossref","is-referenced-by-count":1,"title":["Abordagem \u00e0 Infe\u00e7\u00e3o pelo V\u00edrus Citomeg\u00e1lico em Doentes Submetidos a Transplante Alog\u00e9nico de Progenitores Hematopoi\u00e9ticos"],"prefix":"10.20344","volume":"37","author":[{"given":"Fernando","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ferraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana Ara\u00fajo","family":"Joana Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2077-3356","authenticated-orcid":false,"given":"Andr\u00e9","family":"Silva-Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8464","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"6343","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-08"},{"key":"6344","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26861"},{"key":"6345","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"6346","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000956"},{"key":"6347","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2010.11.011"},{"key":"6348","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679639"},{"key":"6349","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00504.x"},{"key":"6350","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00287-8"},{"key":"6351","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.08.010"},{"key":"6352","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362"},{"key":"6353","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.05.001"},{"key":"6354","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"6355","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0597-6"},{"key":"6356","doi-asserted-by":"publisher","DOI":"10.1086\/339329"},{"key":"6357","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30107-0"},{"key":"6358","unstructured":"European Medicines Agency. Letermovir. [consultado 2024 fev 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevymis."},{"key":"6359","unstructured":"Food and Drug Adminisration. Prevymis full prescribing information. [consultado 2024 fev 28]. Dispon\u00edvel em: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209939Orig1s000,209940Orig1s000lbl.pdf."},{"key":"6360","unstructured":"World Health Organization. Training manual for Enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG. [consultado 2014 jun 28]. Dispon\u00edvel em: https:\/\/ww3.icb.usp.br\/wp-content\/uploads\/2020\/10\/PROTOCOLO-ELISA.pdf."},{"key":"6361","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369573"},{"key":"6362","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.01.027"},{"key":"6363","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.05.015"},{"key":"6364","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15764"},{"key":"6365","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1159"},{"key":"6366","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"6367","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.03.020"},{"key":"6368","unstructured":"European Medicines Agency. Maribavir. [consultado 2024 fev 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/livtencity."},{"key":"6369","unstructured":"European Medicines Agency. Ganciclovir. [consultado 2024 fev 28]. Dispon\u00edvel em: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/cymevene."}],"container-title":["Acta M\u00e9dica Portuguesa"],"original-title":[],"link":[{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/21441\/15459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/download\/21441\/15459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T07:58:23Z","timestamp":1727769503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.actamedicaportuguesa.com\/revista\/index.php\/amp\/article\/view\/21441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.20344\/amp.21441","relation":{},"ISSN":["1646-0758","0870-399X"],"issn-type":[{"value":"1646-0758","type":"electronic"},{"value":"0870-399X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}